Pipeline

19 targets supported by **GENETIC VALIDATION**

The industry's largest toolkit with **11** **MODALITIES***

A mix of **INNOVATIVE MOLECULES, NEW INDICATIONS, AND BIOSIMILARS**

A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness.
Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects.
Human genetic validation is used whenever possible to enhance the likelihood of success.

PHASE ONE

AMG 172 Hematology/ Oncology	**AMG 208** Hematology/ Oncology	**AMG 211** Hematology/ Oncology
AMG 228 Hematology/ Oncology	**AMG 232** Hematology/ Oncology	**AMG 282** Inflammation
AMG 301 Neuroscience	**AMG 319** Hematology/ Oncology	**AMG 357** Inflammation
AMG 557 Inflammation	**AMG 581** Neuroscience	**AMG 595** Hematology/ Oncology
AMG 780 Hematology/ Oncology	**AMG 811** Inflammation	**AMG 820** Hematology/ Oncology
AMG 876 Metabolic Disorders	**AMG 900** Hematology/ Oncology	**Oprozomib** Hematology/ Oncology

PHASE TWO

AMG 139 Inflammation	**AMG 157** Inflammation	**AMG 181** Inflammation
AMG 334 Neuroscience	**AMG 337** Hematology/ Oncology	**BLINCYTO® (blinatumomab)** Hematology/ Oncology
Kyprolis® (carfilzomib) Hematology/ Oncology	**Omecamtiv mecarbil** Cardiovascular	**Oprozomib** Hematology/ Oncology
XGEVA® (denosumab) Hematology/ Oncology		

PHASE THREE

AMG 334 Neuroscience	**Aranesp® (darbepoetin alfa)** Hematology/ Oncology	**BLINCYTO® (blinatumomab)** Hematology/ Oncology
Etelcalcetide (AMG 416) Nephrology	**Kyprolis® (carfilzomib)** Hematology/ Oncology	**Prolia® (denosumab)** Bone Health
Repatha™ (evolocumab) Cardiovascular	**Romosozumab** Bone Health	**Talimogene laherparepvec** Hematology/ Oncology
Trebananib Hematology/ Oncology	**Vectibix® (panitumumab)** Hematology/ Oncology	**XGEVA® (denosumab)** Hematology/ Oncology

BIOSIMILARS‡

ABP 501 (biosimilar adalimumab) Inflammation	**ABP 710 (biosimilar infliximab)** Inflammation	**ABP 980 (biosimilar trastuzumab)** Hematology/ Oncology	**ABP 494 (biosimilar cetuximab)** Hematology/ Oncology	**ABP 215 (biosimilar bevacizumab)** Hematology/ Oncology	**ABP 798 (biosimilar rituximab)** Hematology/ Oncology & Inflammation

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of August 5, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE ONE

Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 172	Antibody-Drug Conjugate	Hematology/ Oncology	AMG 172 is a human anti-CD27L antibody-drug conjugate. It is being investigated in renal cell carcinoma.
AMG 208	Small Molecule	Hematology/ Oncology	AMG 208 is a small molecule inhibitor of MET. It is being investigated as a cancer treatment.
AMG 211	BiTE® Antibody	Hematology/ Oncology	AMG 211 is an anti-CEA x anti-CD3 (BiTE®) bispecific antibody construct. It is being investigated as a cancer treatment in solid tumors. AMG 211 is being jointly developed in collaboration with MedImmune.
AMG 228	Monoclonal Antibody	Hematology/ Oncology	AMG 228 is a monoclonal antibody being investigated for the treatment of solid tumors.
AMG 232	Small Molecule	Hematology/ Oncology	AMG 232 is a small molecule inhibitor of MDM2. It is being investigated as a cancer treatment.
AMG 282	Monoclonal Antibody	Inflammation	AMG 282 is a human antibody that inhibits binding of interleukin-33 to the ST2 receptor. It is being investigated as a treatment for asthma.
AMG 301	Monoclonal Antibody	Neuroscience	AMG 301 is a monoclonal antibody being investigated for the treatment of migraine.
AMG 319	Small Molecule	Hematology/ Oncology	AMG 319 is a small molecule inhibitor of PI3 Kinase delta. It is being investigated in hematologic malignancies.
AMG 357	Small Molecule	Inflammation	AMG 357 is a small molecule. It is being investigated as a treatment for autoimmune diseases.
AMG 557	Monoclonal Antibody	Inflammation	AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus. AMG 557 is being jointly developed in collaboration with AstraZeneca.
AMG 581	Small Molecule	Neuroscience	AMG 581 is a small molecule being investigated for the treatment of schizophrenia.
AMG 595	Antibody-Drug Conjugate	Hematology/ Oncology	AMG 595 is a human anti-epidermal growth factor receptor variant III (anti-EGFRvIII) antibody-drug conjugate. It is being investigated as a treatment for glioblastoma.
AMG 780	Monoclonal Antibody	Hematology/ Oncology	AMG 780 is a human anti-angiopoietin antibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
AMG 811	Monoclonal Antibody	Inflammation	AMG 811 is a human monoclonal antibody that inhibits interferon gamma. It is being investigated as a treatment for systemic lupus erythematosus.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of August 5, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE ONE

Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 820	**Monoclonal Antibody**	**Hematology/ Oncology**	AMG 820 is a human monoclonal antibody that inhibits c-fms and decreases tumor-associated macrophage (TAM) function. It is being investigated as a cancer treatment.
AMG 876	**Fusion Protein**	**Metabolic Disorders**	AMG 876 is a fusion protein. It is being investigated as a treatment for type 2 diabetes
AMG 900	**Small Molecule**	**Hematology/ Oncology**	AMG 900 is a small molecule inhibitor of Aurora kinases A, B, and C. It is being investigated as a cancer treatment.
Oprozomib *oh proz' oh mib*	**Small Molecule**	**Hematology/ Oncology**	Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of hematologic malignancies, with Phase 1b/2 studies ongoing.

PHASE TWO

Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 139	**Monoclonal Antibody**	**Inflammation**	AMG 139 is a human monoclonal antibody that inhibits the action of interleukin-23. It is being investigated as a treatment for Crohn's disease, with a Phase 2 study ongoing. As of April 1, 2015, Amgen has suspended participation in the co-development and commercialization of AMG 139 with AstraZeneca, with the option of resuming such participation at a later date.
AMG 157	**Monoclonal Antibody**	**Inflammation**	AMG 157 is a human monoclonal antibody that inhibits the action of TSLP. It is being investigated as a treatment for asthma, with a Phase 2 study ongoing. AMG 157 is being jointly developed in collaboration with AstraZeneca.
AMG 181	**Monoclonal Antibody**	**Inflammation**	AMG 181 is a human monoclonal antibody that inhibits the action of alpha4/beta7. It is being investigated as a treatment for ulcerative colitis and Crohn's disease, with Phase 2 studies ongoing. AMG 181 is being jointly developed in collaboration with AstraZeneca.
AMG 334	**Monoclonal Antibody**	**Neuroscience**	AMG 334 is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the prevention of migraine. Phase 3 studies in episodic migraine are underway, and the Phase 2 study in chronic migraine is ongoing.
AMG 337	**Small Molecule**	**Hematology/ Oncology**	AMG 337 is a small molecule inhibitor of MET. It is being investigated as a cancer treatment with a Phase 2 study for the treatment of gastric cancer ongoing.
BLINCYTO® (blinatumomab) *blin" a toom' oh mab*	**BiTE® Antibody & Oncolytic Immunotherapy**	**Hematology/ Oncology**	BLINCYTO® is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody. A Phase 3 study in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) is ongoing. Phase 2 studies in adult patients with relapsed/refractory Philadelphia chromosome-positive (Ph+) and minimal residual disease of ALL are ongoing. A Phase 2 study in adult patients with diffuse large B-cell lymphoma (DLBCL) is ongoing.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

PHASE TWO

Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
Kyprolis® (carfilzomib) *car fil' zoe mib*	**Small Molecule**	**Hematology/ Oncology**	Kyprolis® is a proteasome inhibitor. It is being investigated as a treatment for patients with multiple myeloma and small-cell lung cancer. Amgen has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Kyprolis® to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy based on the data from the global Phase 3 ASPIRE (CArfilzomib, Lenalidomide and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial. In July 2015, Amgen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Kyprolis® to seek an expanded indication for the treatment of patients with relapsed multiple myeloma, who have received at least one prior therapy, based on data from the global Phase 3 ENDEAVOR (RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma) trial. A Phase 3 study, CLARION, evaluating Kyprolis® in combination with melphalan and prednisone compared to bortezomib, melphalan and prednisone in newly diagnosed multiple myeloma is ongoing. A Phase 3 study, ARROW, with weekly dosing in relapsed and refractory multiple myeloma is also underway.
Omecamtiv mecarbil *om" e kam' tiv me kar' bil*	**Small Molecule**	**Cardiovascular**	Omecamtiv mecarbil is a small molecule activator of cardiac myosin. It is being investigated for the treatment of heart failure. Amgen is developing this product in collaboration with Cytokinetics. A Phase 2 dose escalation study to select and evaluate an oral modified release formulation of omecamtiv mecarbil in subjects with heart failure and left ventricular systolic dysfunction is ongoing.
Oprozomib *oh proz' oh mib*	**Small Molecule**	**Hematology/ Oncology**	Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of hematologic malignancies, with Phase 1b/2 studies ongoing.
XGEVA® (denosumab) *den oh sue' mab*	**Monoclonal Antibody**	**Hematology/ Oncology**	Denosumab is a human monoclonal antibody that inhibits RANKL. Phase 3 studies of XGEVA® for the delay or prevention of bone metastases in patients with adjuvant breast cancer and prevention of skeletal-related events (SREs) in patients with multiple myeloma are ongoing. A Phase 2 study in non-small cell lung cancer is ongoing.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 334	**Monoclonal Antibody**	**Neuroscience**	AMG 334 is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the prevention of migraine. Phase 3 studies in episodic migraine are underway, and the Phase 2 study in chronic migraine is ongoing.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of August 5, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
Aranesp® (darbepoetin alfa) *dar" be poe' e tin al fa*	**Therapeutic Protein**	**Hematology/ Oncology**	Aranesp® is a recombinant human protein agonist of the erythropoietin receptor. A Phase 3 study of Aranesp® for the treatment of low risk myelodysplastic syndromes is ongoing.
BLINCYTO® (blinatumomab) *blin" a toom' oh mab*	**BiTE® Antibody & Oncolytic Immunotherapy**	**Hematology/ Oncology**	BLINCYTO® is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody. A Phase 3 study in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) is ongoing. Phase 2 studies in adult patients with relapsed/refractory Philadelphia chromosome-positive (Ph+) and minimal residual disease of ALL are ongoing. A Phase 2 study in adult patients with diffuse large B-cell lymphoma (DLBCL) is ongoing.
Etelcalcetide (AMG 416) *e" tel kal' se tide*	**Peptide**	**Nephrology**	Etelcalcetide (AMG 416) is a peptide agonist of the human cell surface calcium-sensing receptor (CaSR). It is being investigated as a treatment of secondary hyperparathyroidism (SHPT) that is administered intravenously in patients with chronic kidney disease who are receiving hemodialysis.
Kyprolis® (carfilzomib) *car fil' zoe mib*	**Small Molecule**	**Hematology/ Oncology**	Kyprolis® is a proteasome inhibitor. It is being investigated as a treatment for patients with multiple myeloma and small-cell lung cancer. Amgen has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Kyprolis® to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy based on the data from the global Phase 3 ASPIRE (CArfilzomib, Lenalidomide and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial. In July 2015, Amgen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Kyprolis® to seek an expanded indication for the treatment of patients with relapsed multiple myeloma, who have received at least one prior therapy, based on data from the global Phase 3 ENDEAVOR (RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma) trial. A Phase 3 study, CLARION, evaluating Kyprolis® in combination with melphalan and prednisone compared to bortezomib, melphalan and prednisone in newly diagnosed multiple myeloma is ongoing. A Phase 3 study, ARROW, with weekly dosing in relapsed and refractory multiple myeloma is also underway.
Prolia® (denosumab) *den oh sue' mab*	**Monoclonal Antibody**	**Bone Health**	Denosumab is a human monoclonal antibody that inhibits RANKL. A Phase 3 study of Prolia® for the treatment of glucocorticoid-induced osteoporosis is ongoing.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of August 5, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
Repatha™ (evolocumab) *e" voe lok' ue mab*	**Monoclonal Antibody**	**Cardiovascular**	Repatha™ is a human monoclonal antibody that inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). It is being investigated in multiple Phase 3 trials as a treatment for dyslipidemia. Amgen has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Repatha™ seeking approval for the treatment of high cholesterol. Amgen has also submitted an application seeking marketing approval of Repatha™ for the treatment of high cholesterol to the Ministry of Health, Labour and Welfare in Japan. Additional Phase 3 studies to evaluate Repatha™ for cardiovascular outcomes, on cognitive function, in statin-intolerant subjects, in subjects with genetic low-density lipoprotein disorders, and with intravascular ultrasound are ongoing. Repatha™ is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
Romosozumab *roe" moe soz' ue mab*	**Monoclonal Antibody**	**Bone Health**	Romosozumab is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being investigated as a treatment for bone loss. Romosozumab is being developed in collaboration with UCB. Phase 3 studies for the treatment of postmenopausal women with osteoporosis and male osteoporosis are ongoing.
Talimogene laherparepvec *tal im' oh jeen la her" pa rep' vek*	**Oncolytic Immuno-therapy**	**Hematology/ Oncology**	Talimogene laherparepvec is an oncolytic immunotherapy derived from HSV-1. It is being investigated as a cancer treatment. A Biologics License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) as has a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for talimogene laherparepvec for the treatment of patients with regionally or distantly metastatic melanoma. A trial to evaluate talimogene laherparepvec in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with mid- to late-stage metastatic melanoma is ongoing.
Trebananib *tre ban' a nib*	**Peptibody**	**Hematology/ Oncology**	Trebananib is a peptibody that inhibits Ang1 and Ang2. It is being investigated as a cancer treatment. In April 2015, Amgen announced that is has stopped administration of blinded investigational product in the Phase 3 study of trebananib in first-line ovarian cancer based on a recommendation by the Data Safety Monitoring Committee, who deemed the study unlikely to achieve its primary progression-free survival endpoint.
Vectibix® (panitumumab) *pan i tu mue' mab*	**Monoclonal Antibody**	**Hematology/ Oncology**	Vectibix® is a human monoclonal antibody antagonist of the epidermal growth factor receptor (EGFr). It is being investigated as a cancer treatment. A Phase 3 study evaluating the survival benefit of Vectibix® plus best supportive care (BSC) compared with BSC alone in subjects with chemorefractory, wild-type KRAS exon 2 mCRC is ongoing.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of August 5, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
XGEVA® (denosumab) *den oh sue' mab*	**Monoclonal Antibody**	**Hematology/ Oncology**	Denosumab is a human monoclonal antibody that inhibits RANKL. Phase 3 studies of XGEVA® for the delay or prevention of bone metastases in patients with adjuvant breast cancer and prevention of skeletal-related events (SREs) in patients with multiple myeloma are ongoing. A Phase 2 study in non-small cell lung cancer is ongoing.

BIOSIMILARS‡

A biosimilar, or follow-on biologic, is a biologic medicine designed to have active properties similar to one that has previously been licensed. Biosimilars follow a different regulatory review pathway than innovative products and indications.

MOLECULE NAME	MODALITY	THERAPEUTIC AREA	DESCRIPTION
ABP 215 (biosimilar bevacizumab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 215 (biosimilar bevacizumab) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody. The reference product primary conditions are colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, breast cancer and ovarian cancer.
ABP 494 (biosimilar cetuximab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 494 (biosimilar cetuximab) is an anti-epidermal growth factor receptor (anti-EGFr) monoclonal antibody. The reference product primary conditions are colorectal cancer and head and neck cancer.
ABP 501 (biosimilar adalimumab)	**Monoclonal Antibody**	**Inflammation**	ABP 501 (biosimilar adalimumab) is an anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody. The reference product primary conditions are rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis.
ABP 710 (biosimilar infliximab)	**Monoclonal Antibody**	**Inflammation**	ABP 710 (biosimilar infliximab) is an anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody. The reference product primary conditions are rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis and ankylosing spondylitis.
ABP 798 (biosimilar rituximab)	**Monoclonal Antibody**	**Hematology/ Oncology & Inflammation**	ABP 798 (biosimilar rituximab) is an anti-CD20 monoclonal antibody. The reference product primary conditions are non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
ABP 980 (biosimilar trastuzumab)	**Monoclonal Antibody**	**Hematology/ Oncology**	ABP 980 (biosimilar trastuzumab) is an anti-HER2 monoclonal antibody. The reference product primary conditions are HER2+ breast cancer and HER2+ gastric cancer.

** Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.*
‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of August 5, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.